Skip to main content

Table 1 Baseline characteristics of SLS II participants with CXCL4 measurements at baseline

From: Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

  Cyclophosphamide Mycophenolate
Characteristic N   N  
Age (years) 71 52.3 ± 9.5 65 52.6 ± 10.0
Female sex (% of patients) 71 77.5 65 69.2
Duration of scleroderma (years) 70 2.5 ± 1.8 63 2.7 ± 1.7
% Limited/% diffuse 71 45.1/54.9 65 36.9/63.1
FVC (%-predicted) 71 66.2 ± 9.9 65 66.6 ± 8.2
FEV1:FVC (%-predicted) 71 83.5 ± 5.6 65 81.8 ± 5.7
TLC (%-predicted) 71 65.4 ± 12.1 65 66.5 ± 10.2
DLCO (%-predicted)a 71 53.8 ± 14.2 65 54.4 ± 11.3
DL/VA (%-predicted) 71 61.0 ± 13.7 65 60.9 ± 11.8
Mahler Dyspnea Index (focal score) 67 7.0 ± 2.3 61 7.3 ± 2.1
Skin-thickening score (mRSS)b     
 All patients 71   65  
  Mean   14.1 ± 10.8   15.2 ± 10.1
  Range   2–46   1–41
 Patients with dcSSc 39   41  
  Mean   20.7 ± 9.9   20.7 ± 8.6
  Range   3–46   4–41
 Patients with lcSSc 32   24  
  Mean   6.1 ± 4.3   5.9 ± 3.4
  Range   2–18   1–14
HAQ disability index (0–3)c 71 0.7 ± 0.7 65 0.7 ± 0.6
QLF-WL 69 9.1 ± 7.0 62 8.2 ± 6.9
QLF-LM 69 23.2 ± 19.2 62 22.5 ± 19.9
QILD-WL 69 32.1 ± 14.2 62 27.2 ± 13.6
QILD-LM 69 53.2 ± 19.3 62 49.8 ± 21.0
Auto-antibody (% positive in patients tested)     
 ANA 70 94.3 62 96.8
 Topoisomerase-1 70 45.7 62 46.2
 RNA polymerase III 70 11.4 62 14.5
 Centromere 70 2.9 62 1.6
 Th\to 67 7.5 60 5.0
  1. Values are mean ± standard deviation, unless otherwise noted
  2. aAdjusted for hemoglobin
  3. bScores for skin thickening (mRSS) can range from 0 to 51, with higher scores indicating more severe thickening
  4. cScores for HAQ Disability Index can range from 1 to 3, with higher numbers indicating greater disability
  5. FVC forced vital capacity, FEV 1 forced expired volume in 1 second, TLC total lung capacity, DLCO diffusing capacity of the lung for carbon monoxide, DL/VA ratio of DLCO to alveolar volume, mRSS modified Rodnan skin score, dcScc diffuse cutaneous systemic sclerosis, lcSSc limited or cutaneous systemic sclerosis, HAQ Health Assessment Questionnaire, QLF quantitative extent of lung fibrosis on high-resolution chest computed tomography, QILD quantitative extent of total interstitial lung disease (including fibrosis, honeycomb, and ground glass opacity), WL whole lung, LM lobe of maximal involvement
  6. ANA Anti-nuclear antibody, Th/To Th/To ribonucleoprotein antibody